Skip to content

Matthew N Hill

7 papers in the library · 9 citations · publishing 2004-2026

Papers

Sort Most recent Most cited

The effect of methamphetamine and 3,4-methylenedioxymethamphetamine on peripheral endocannabinoid concentrations: a study in healthy adults.

Psychopharmacology February 1, 2026 Ana Deutsch, Connor J Haggarty, Gavin N Petrie et al. 1 citation

Stimulant drugs such as methamphetamine (MA) and 3,4-methylenedioxymethamphetamine (MDMA) can impact neurobiological systems implicated in stress, reward processing, and drug use. Although recent preclinical evidence implicates the endocannabinoid (eCB) system in these processes, little is known about the acute effects of stimulants on eCB levels in humans. The aim of the present study was to...

Acute and chronic cannabis vapor exposure produces immediate and delayed impacts on phases of fear learning in a sex specific manner.

Psychopharmacology February 1, 2026 Savannah H M Lightfoot, Andrei S Nastase, Gabriela Costa Lenz Cesar et al.

Current treatment options for PTSD have unreliable efficacy, with many individuals unable to achieve complete remission. Cannabis and cannabinoids that act through the endogenous cannabinoid (endocannabinoid) system to help promote trauma recovery by means of enhanced extinction learning are potential therapeutic, pharmacological candidates. Using a preclinical model of translationally-relevant...

Dose-dependent effect of acute THC on extinction memory recall and fear renewal: a randomized, double-blind, placebo-controlled study.

Psychopharmacology February 1, 2026 Nicole L Zabik, Allesandra Iadipaolo, Craig A Peters et al.

Prior work from our lab and others demonstrates that the endocannabinoid system is a promising avenue for improving fear memory deficits in posttraumatic stress disorder (PTSD). Specifically, 7.5 mg of delta-9-tetrahydrocannabinol (THC) decreases fear responding in healthy adults and increases prefrontal cortex activation during extinction learning and fear renewal in adults with PTSD. The...

Cannabis produces acute hyperphagia in humans and rodents via increased reward valuation for, and motivation to, acquire food.

Proceedings of the National Academy of Sciences of the United States of America December 30, 2025 Catherine Hume, Carrie Cuttler, Samantha L Baglot et al.

With approximately 4% of the world's population using cannabis, there is a need to better understand its physiological effects. Cannabis consumption acutely promotes food intake ("the munchies") via delta-9-tetrahydrocannabinol-mediated activation of cannabinoid 1 receptors (CB1R); however, these appetitive effects have not been well characterized. We examined effects of cannabis vapor...

Challenges and considerations for treating PTSD with medicinal cannabis: the Australian clinician's perspective.

Expert Review of Clinical Pharmacology 2023 Luke J. Ney, Wole Akosile, Chris Davey et al. 8 citations

Preclinical and experimental research have provided promising evidence that medicinal cannabis may be efficacious in the treatment of posttraumatic stress disorder (PTSD). However, implementation of medicinal cannabis into routine clinical therapies may not be straightforward. In this review, we describe some of the clinical, practical, and safety challenges that must be addressed for...

Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models

British Journal of Pharmacology June 1, 2010 Daniel T Malone, Matthew N Hill, Tiziana Rubino

Cannabis is one of the most widely used illicit drugs among adolescents, and most users first experiment with it in adolescence. Adolescence is a critical phase for brain development, characterized by neuronal maturation and rearrangement processes, such as myelination, synaptic pruning and dendritic plasticity. The endocannabinoid system plays an important role in fundamental brain...

Prolonged cannabinoid treatment results in spatial working memory deficits and impaired long-term potentiation in the CA1 region of the hippocampus in vivo.

The European journal of neuroscience August 2004 Matthew N Hill, David J Froc, Christopher J Fox et al.

Adult male Long-Evans rats were administered the potent cannabinoid 1 receptor agonist HU-210 (100 microg/kg, i.p.) for 15 days continuously and their performance on a matching-to-place version of the Morris water maze was subsequently evaluated. Overall, experimental animals performed significantly worse initially on the reference memory component of this task, but their performance improved...